PTC THERAPEUTICS INC (PTCT)

US69366J2006 - Common Stock

45.845  +0.49 (+1.09%)

Fundamental Rating

2

PTCT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. PTCT has a bad profitability rating. Also its financial health evaluation is rather negative. PTCT is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year PTCT has reported negative net income.
In the past year PTCT has reported a negative cash flow from operations.
PTCT had negative earnings in each of the past 5 years.
In the past 5 years PTCT always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -24.60%, PTCT is in the better half of the industry, outperforming 72.95% of the companies in the same industry.
Industry RankSector Rank
ROA -24.6%
ROE N/A
ROIC N/A
ROA(3y)-30.95%
ROA(5y)-25.64%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 92.20%, PTCT belongs to the best of the industry, outperforming 94.13% of the companies in the same industry.
PTCT's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for PTCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-0.47%

More info and screens

2

2. Health

2.1 Basic Checks

PTCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
PTCT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PTCT has more shares outstanding
Compared to 1 year ago, PTCT has a worse debt to assets ratio.

2.2 Solvency

PTCT has an Altman-Z score of -1.31. This is a bad value and indicates that PTCT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.31, PTCT is in line with its industry, outperforming 56.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.31
ROIC/WACCN/A
WACC9.57%

2.3 Liquidity

PTCT has a Current Ratio of 2.10. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.10, PTCT is doing worse than 74.73% of the companies in the same industry.
A Quick Ratio of 2.04 indicates that PTCT has no problem at all paying its short term obligations.
With a Quick ratio value of 2.04, PTCT is not doing good in the industry: 73.84% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.1
Quick Ratio 2.04

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.94% over the past year.
The Revenue has grown by 12.84% in the past year. This is quite good.
The Revenue has been growing by 28.79% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)49.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.02%
Revenue 1Y (TTM)12.84%
Revenue growth 3Y35.04%
Revenue growth 5Y28.79%
Sales Q2Q%0.11%

3.2 Future

Based on estimates for the next years, PTCT will show a very strong growth in Earnings Per Share. The EPS will grow by 20.84% on average per year.
The Revenue is expected to grow by 4.73% on average over the next years.
EPS Next Y25.92%
EPS Next 2Y37.61%
EPS Next 3Y20.23%
EPS Next 5Y20.84%
Revenue Next Year-15.97%
Revenue Next 2Y-2.15%
Revenue Next 3Y-1.99%
Revenue Next 5Y4.73%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PTCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PTCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PTCT indicates a rather cheap valuation: PTCT is cheaper than 92.88% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 232.58

4.3 Compensation for Growth

A more expensive valuation may be justified as PTCT's earnings are expected to grow with 20.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.61%
EPS Next 3Y20.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PTCT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PTC THERAPEUTICS INC

NASDAQ:PTCT (12/26/2024, 2:28:05 PM)

45.845

+0.49 (+1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners106.12%
Inst Owner Change-1.03%
Ins Owners0.51%
Ins Owner Change0%
Market Cap3.54B
Analysts71.82
Price Target47.07 (2.67%)
Short Float %6.11%
Short Ratio5.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.6%
Min EPS beat(2)-18.68%
Max EPS beat(2)5.49%
EPS beat(4)2
Avg EPS beat(4)-38.87%
Min EPS beat(4)-147.48%
Max EPS beat(4)5.49%
EPS beat(8)2
Avg EPS beat(8)-46.34%
EPS beat(12)2
Avg EPS beat(12)-40.42%
EPS beat(16)3
Avg EPS beat(16)-33.26%
Revenue beat(2)1
Avg Revenue beat(2)5.25%
Min Revenue beat(2)-1.23%
Max Revenue beat(2)11.74%
Revenue beat(4)2
Avg Revenue beat(4)6.4%
Min Revenue beat(4)-6.31%
Max Revenue beat(4)21.39%
Revenue beat(8)4
Avg Revenue beat(8)1.64%
Revenue beat(12)7
Avg Revenue beat(12)2.8%
Revenue beat(16)11
Avg Revenue beat(16)4.48%
PT rev (1m)14.92%
PT rev (3m)22.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)41.53%
EPS NY rev (1m)5.9%
EPS NY rev (3m)6.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)34.76%
Revenue NY rev (1m)6.3%
Revenue NY rev (3m)7.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.93
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 232.58
EPS(TTM)-4.1
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-2.42
FCFYN/A
OCF(TTM)-2.31
OCFYN/A
SpS11.68
BVpS-13.67
TBVpS-19.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.6%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.2%
FCFM N/A
ROA(3y)-30.95%
ROA(5y)-25.64%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-0.47%
F-Score3
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 112.78
Cap/Depr 5.55%
Cap/Sales 0.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.1
Quick Ratio 2.04
Altman-Z -1.31
F-Score3
WACC9.57%
ROIC/WACCN/A
Cap/Depr(3y)26.95%
Cap/Depr(5y)32.93%
Cap/Sales(3y)4.28%
Cap/Sales(5y)4.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.02%
EPS Next Y25.92%
EPS Next 2Y37.61%
EPS Next 3Y20.23%
EPS Next 5Y20.84%
Revenue 1Y (TTM)12.84%
Revenue growth 3Y35.04%
Revenue growth 5Y28.79%
Sales Q2Q%0.11%
Revenue Next Year-15.97%
Revenue Next 2Y-2.15%
Revenue Next 3Y-1.99%
Revenue Next 5Y4.73%
EBIT growth 1Y66.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year78.77%
EBIT Next 3Y30.71%
EBIT Next 5YN/A
FCF growth 1Y36.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.43%
OCF growth 3YN/A
OCF growth 5YN/A